On Monday, C4 Therapeutics Inc (CCCC) stock saw a modest uptick, ending the day at $6.45 which represents a slight increase of $0.84 or 14.97% from the prior close of $5.61. The stock opened at $5.58 ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on C4 Therapeutics (CCCC – Research Report) today and set a price target of ...

Hebron Christian’s valiant effort came up just short in Friday’s Region 8-AA football championship game against Prince Avenue ...

One person is dead Friday night after a shooting on Neill Avenue in East Nashville. Detectives with the Metro Nashville ...

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ...

C4 Therapeutics, Inc. ( (CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its ...

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 12.50% and 158.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

This power purchase agreement with Meta contributes to ENGIE closing almost 1 GW of signed PPAs in the U.S. for 2024 (YTD).

WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...

The Wenatchee City Council on Thursday approved a service agreement to replace the city's four million gallon water reservoir ...

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the ...